Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 883 shares at $52.76 ($47K) on 2023-01-30, disclosed to the SEC on 2023-01-31.
Scheduled sale ($47k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |